ClinicalTrials.gg
RecruitingNCT07469306Updated Oct 1, 2026

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

A Phase 2 interventional study of Modified Short-course radiotherapy and Long-course radiotherapy in Locally Advanced Rectal Cancer, sponsored by Fujian Cancer Hospital. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Fujian Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
149th of 373
130 · median 100
Started
2026
with 50 others
Phase 2
155 of 463
95 open now
Primary completion
2027-08
later than 170 of 266 live
Registered
417th of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 149th largest by planned enrollment of the 373 interventional ones that give a count, is one of 51 that started in 2026, is one of 155 in phase 2, reaches primary completion later than 170 of the 266 other live ones, and was the 417th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

222 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.

Read the detailed description

In the exploration of treatments for locally advanced rectal cancer (LARC), the novel model combining short-course radiotherapy with CAPOX chemotherapy and PD-1 inhibitor (tislelizumab) is demonstrating promising potential. By comparing the efficacy and safety of modified short-course radiotherapy versus traditional long-course radiotherapy within this combination regimen, this study aims to identify the optimal radiotherapy strategy to maximize tumor regression and improve the complete response rate, thereby offering a more promising treatment option for rectal cancer patients seeking organ preservation.

03

Conditions studied

  • Locally Advanced Rectal Cancer

Browse trials for

Keywords

  • Modified Short-course radiotherapy (mSCRT)
  • Long-course radiotherapy (LCRT)
  • CAPOX
  • PD-1 monoclonal antibody
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years, any gender.
  • confirmed rectal adenocarcinoma.
  • Baseline MR stage T3-4/N+.
  • Distance from anal verge ≤12cm.
  • No distant .
  • Performance Status ≥70.
  • Adequate organ function, no to surgery, radiotherapy, or immunotherapy.
  • Microsatellite/mismatch repair status MSS/pMMR.
  • No prior chemotherapy or any other anti-tumor treatment before inclusion.
  • No prior immunotherapy.
  • Ability to comply with the study protocol during the study period.
  • Signed written .

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • Pathological diagnosis of signet ring cell carcinoma.
  • History of other within the past 5 years, except cured skin cancer and cervical carcinoma in situ.
  • Uncontrolled epilepsy, central nervous system disorders, or history of psychiatric disorders that, in the opinion of the investigator, may interfere with signing the form or affect patient compliance with oral medication.
  • (i.e., active) cardiac disease, such as symptomatic coronary artery disease, (NYHA) Class II or greater congestive heart failure, or significant arrhythmias requiring drug intervention (see Appendix 12), or history of myocardial infarction within the past 12 months.
  • Organ transplant recipients requiring therapy and long-term users.
  • Patients with diseases.
  • Severe uncontrolled recurrent infections or other severe uncontrolled comorbidities.
  • Subjects with baseline hematological and biochemical parameters not meeting the following criteria: ≥90g/L; (ANC) .≥1.5×10\^9/L; ≥100×10\^9/L; , AST ≤2.5 times the ; ALP

    ≤2.5 times the upper limit of normal; serum total \<1.5 times the upper limit of normal; serum creatinine \<1 times the upper limit of normal; serum albumin ≥30g/L.

  • Known deficiency of dihydropyrimidine dehydrogenase (DPD).
  • Allergy to any drug components.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Modified Short-course radiotherapy Combined with CAPOX plus Tislelizumab

    Modified Short-course radiotherapy (GTV-P: 30 Gy/5f , CTV-P: 22.5 Gy/5 f),followed by Oxaliplatin ,Capecitabine and Tislelizumab q3w \*4 cycles.Efficacy and surgery were assessed after the end of treatment.

    Radiation: Modified Short-course radiotherapy · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Tislelizumab

  • Active comparator
    Long-course radiotherapy Combined with Capecitabine and Tislelizumab

    Long-course radiotherapy (50.4 Gy/25 f) with concurrent Capecitabine (on radiation days) and Tislelizumab (q3w, 3cycles).Efficacy and surgery were assessed after the end of treatment.

    Radiation: Long-course radiotherapy · Drug: Capecitabine · Drug: Tislelizumab

Interventions

  • RadiationModified Short-course radiotherapy

    Rectal lesion + metastatic lymph nodes, GTV 30Gy/5Fx. Pelvic lymphatic drainage area, CTV 22.5Gy/5Fx.

  • RadiationLong-course radiotherapy

    Rectal lesion + metastatic lymph nodes+pelvic lymphatic drainage area,50.4 Gy/25 f

  • 130 mg/m²,d1, q3w ,4 cycles

  • 1000 mg/m, d1-14,bid,q3w, 4 cycles

  • 200mg,d1,q3w,4 cycles

  • 825 mg/m² ,BID ,on radiation days

  • 200mg,d1,q3w,3 cycles

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate

    Including pCR and CCR.

    Time frame: t 3 months after completion of neoadjuvant therapy and up to 12 months after enrollment.

Secondary outcomes

  1. Organ Preservation Rate

    Sphincter-saving rate in enrolled patients

    Time frame: 1 year.

  2. Surgical Complications

    Incidence and severity of postoperative complications.

    Time frame: Within 30 days post-surgery

  3. the Quality of Life

    EORTC Core Quality of Life questionnaire (QLQ-C30)#range from 0-100, with comprehensive assessment indicators, including positive and negative indicators.

    Time frame: Baseline, before surgery, and up to 12 months after surgery

  4. Grade ≥3 Adverse Event Rate

    Incidence of grade 3 or higher adverse events graded according to CTCAE v4.0.

    Time frame: From start of treatment to 30 days after last dose, up to approximately 6 months

  5. 3y-DFS

    Proportion of patients without disease recurrence or death from any cause at 3 years.

    Time frame: From enrollment to 36 month

  6. 3y-LRFS

    Proportion of patients without local recurrence at 3 years.

    Time frame: From enrollment to 36 month

  7. 3y-OS

    Proportion of patients alive at 3 years.

    Time frame: From enrollment to 36 month

07

Study locations

1 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 11 months is below that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 13, 2026
StartActual
Aug 15, 2026
Primary completionEst.
Aug 10, 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • Fujian Cancer Hospital · Fuzhou, Chinano status→Recruiting
  • The Second Hospital of Longyan · Longyan, Chinano status→Not yet recruiting
  • Jinjiang Municipal Hospital · Quanzhou, Chinano status→Not yet recruiting
Oct 1, 2026
Start date
Aug 10, 2026→Aug 15, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • Fujian Cancer Hospital · Fuzhou, Chinano status→Recruiting
    • The Second Hospital of Longyan · Longyan, Chinano status→Not yet recruiting
    • Jinjiang Municipal Hospital · Quanzhou, Chinano status→Not yet recruiting
    Start date Aug 10, 2026→Aug 15, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07469306
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Aug 15, 2026
Primary completion
Aug 10, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Jinluan Li, MD
Contact
lijinluan@fjmu.edu.cn
15159628678 ext. +86
Chunkang Yang, MD
Contact
chunk330@163.com
13509333116 ext. +86
Jiunluan Li, MD
principal investigator · Fujian Cancer Hospital
Chunkang Yang, MD
principal investigator · Fujian Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion